サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：アルファサラセミア治療の世界市場－成長、将来展望、競合分析（2022年～2030年）
市場調査レポート
商品コード
1149078

アルファサラセミア治療の世界市場－成長、将来展望、競合分析（2022年～2030年）

Alpha Thalassemia Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 120 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
アルファサラセミア治療の世界市場－成長、将来展望、競合分析（2022年～2030年）
出版日: 2022年08月24日
発行: Acute Market Reports
ページ情報: 英文 120 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のアルファサラセミア治療の市場規模は、2021年に6億4,340万米ドルに達し、2022年から2030年までのCAGRは7.1%と予測されています。医療従事者や一般市民のサラセミアに関連する意識の高まり、サラセミアを管理・治療するために政府・非政府組織から提供される支援は、アルファサラセミア治療市場の成長を促進しています。

当レポートでは、世界のアルファサラセミア治療市場について調査分析し、ビジネス展望、市場力学、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

  • レポートの説明
    • レポートの目的
    • 対象者
    • 主な製品
  • 市場セグメンテーション
  • 調査手法
    • フェーズⅠ－2次調査
    • フェーズⅡ－1次調査
    • フェーズⅢ－専門家による審査
    • 仮定
    • 採用されたアプローチ

第2章 エグゼクティブサマリー

  • 市場スナップショット：世界のアルファサラセミア治療市場
  • 世界のアルファサラセミア治療市場（100万米ドル）（2021年）
  • 世界のアルファサラセミア治療市場（100万米ドル）（2021年）：薬剤タイプ別
  • 世界のアルファサラセミア治療市場（100万米ドル）（2021年）：地域別
  • COVID-19の影響
  • 魅力的な投資提案（2021年）：地域別
  • 競合分析
    • 主要なアルファサラセミア治療市場ベンダーの市場ポジショニング
    • アルファサラセミア治療市場のベンダーが採用する戦略
    • 主要な業界戦略

第3章 アルファサラセミア治療市場：ビジネス展望と市場力学

  • イントロダクション
  • 世界のアルファサラセミア治療市場金額（100万米ドル）（2020年～2030年）
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析
  • ポーターのファイブフォースモデル
    • サプライヤーの力
    • バイヤーの力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競争企業間の敵対関係
  • PESTEL分析
    • 政治的
    • 経済的
    • 技術的
    • 法的
    • 社会的

第4章 アルファサラセミア治療市場：米ドル（100万）（2020年～2030年）

  • 市場概要
  • 成長と収益分析：2021年と2030年の比較
  • 市場セグメンテーション

第5章 アルファサラセミア治療市場、米ドル（100万）（2020年～2030年）：薬剤タイプ別

  • 市場概要
  • 成長と収益分析：2021年と2030年の比較
  • 市場セグメンテーション
    • 葉酸
    • デフェラシロクス
    • デフェリプロン
    • ヒドロキシウレア

第6章 北米のアルファサラセミア治療市場、米ドル（100万）（2020年～2030年）

第7章 英国および欧州連合のアルファサラセミア治療市場、米ドル（100万）（2020年～2030年）

第8章 アジア太平洋のアルファサラセミア治療市場、米ドル（100万）（2020年～2030年）

第9章 ラテンアメリカのアルファサラセミア治療市場、米ドル（100万）（2020年～2030年）

第10章 中東およびアフリカのアルファサラセミア治療市場、米ドル（100万）（2020年～2030年）

第11章 企業プロファイル

  • GlaxoSmithKline Plc
  • Bellicum Pharmaceuticals
  • Novartis AG
  • Acceleron Pharma
  • Johnson & Johnson
  • Merck & Co Inc.
  • Alnylam Pharmaceuticals Inc.
  • Calimmune Inc.
  • Editas Medicine Inc.
  • Gilead Sciences Inc.
図表

List of Tables

  • TABLE 1 Global Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
  • TABLE 2 Global Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 3 North America Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
  • TABLE 4 North America Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 5 UK and European Union Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
  • TABLE 6 UK and European Union Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 7 Asia Pacific Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
  • TABLE 8 Asia Pacific Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 9 Latin America Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
  • TABLE 10 Latin America Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 11 Middle East and Africa Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
  • TABLE 12 Middle East and Africa Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Alpha Thalassemia Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Alpha Thalassemia Treatment Market: Quality Assurance
  • FIG. 5 Global Alpha Thalassemia Treatment Market, By , 2021
  • FIG. 6 Global Alpha Thalassemia Treatment Market, By Drug Type, 2021
  • FIG. 7 Global Alpha Thalassemia Treatment Market, By Geography, 2021
  • FIG. 8 Global Alpha Thalassemia Treatment Market, By , 2021 Vs 2030, %
  • FIG. 9 Global Alpha Thalassemia Treatment Market, By Drug Type, 2021 Vs 2030, %
  • FIG. 10 U.S. Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 11 Canada Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 12 Rest of North America Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 13 UK Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 Germany Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 Spain Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 Italy Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 France Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 Rest of Europe Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 China Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 Japan Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 India Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 Australia Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 South Korea Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 Rest of Asia Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Brazil Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 Mexico Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Rest of Latin America Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 GCC Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 29 Africa Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 30 Rest of Middle East and Africa Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
目次
Product Code: 138733-08-22

Industry Outlook

Alpha thalassemia treatment market accounted for a market value of US$ 643.4 Mn in 2021 and projected to grow at a CAGR of 7.1% during the forecast period from 2022 to 2030. Alpha thalassemia is a congenital autosomal recessive disorder caused due to absence or reduction in alpha globin peptides due to a deletion or mutation of the alpha globin genes. Alpha thalassemia usually found in Africa, the Middle East, India, Southeast Asia, southern China, and the Mediterranean region. The key factors responsible for growth of alpha thalassemia treatment market are the rising awareness associated with thalassemia in medical practitioners & public, and support provided by government & non-government organizations to manage and treat thalassemia.

Deferasirox being the only approved drug for alpha thalassemia treatment will dominate the market throughout the forecast period

In 2021, deferasirox will dominate the market throughout the forecast period as it is the only approved drug therapy by USFDA for alpha thalassemia. According to market experts, deferasirox possess efficient oral bioavailability and a long half-life appropriate for once-daily dosing. Overall, deferasirox is similar to deferoxamine in reducing liver iron and serum ferritin levels in a dose-dependent style. It is use widely across the world for alpha thalassemia treatment because its once-per-day oral dosage. However, Darbepoetin Alfa is present in phase III of clinical trials and expected to get approval very soon but there are a few drawbacks observed in the Phase IIa that might have some effect on its approval. If it gets approved it will be observed as the fastest growing drug in this market.

Increasing awareness related to the treatment & management of alpha thalassemia in Asia Pacific makes it the fastest growing region throughout the forecast period

The Asia Pacific will grow gradually throughout the forecast period from 2020 to 2030, the key factors responsible for growth of alpha thalassemia treatment market in this region are rising awareness related to alpha thalassemia treatment & management and increasing support provided by governmental & non-governmental organizations to develop awareness in public. According to market experts, alpha-thalassemia is specifically common among Southeast Asian population descent 1-30% of the population has a thalassemia trait; up to 40% may be a genetic carrier.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Alpha Thalassemia Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Alpha Thalassemia Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Type

  • Folic Acid
  • Deferasirox
  • Deferiprone
  • Hydroxyurea

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Alpha Thalassemia Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Alpha Thalassemia Treatment market?
  • Which is the largest regional market for Alpha Thalassemia Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Alpha Thalassemia Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Alpha Thalassemia Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Alpha Thalassemia Treatment Market
  • 2.2. Global Alpha Thalassemia Treatment Market, By , 2021 (US$ Million)
  • 2.3. Global Alpha Thalassemia Treatment Market, By Drug Type, 2021 (US$ Million)
  • 2.4. Global Alpha Thalassemia Treatment Market, By Geography, 2021 (US$ Million)
  • 2.5. Impact of Covid 19
  • 2.6. Attractive Investment Proposition by Geography, 2021
  • 2.7. Competitive Analysis
    • 2.7.1. Market Positioning of Key Alpha Thalassemia Treatment Market Vendors
    • 2.7.2. Strategies Adopted by Alpha Thalassemia Treatment Market Vendors
    • 2.7.3. Key Industry Strategies

3. Alpha Thalassemia Treatment Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Alpha Thalassemia Treatment Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation

5. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Folic Acid
    • 5.3.2. Deferasirox
    • 5.3.3. Deferiprone
    • 5.3.4. Hydroxyurea

6. North America Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
  • 6.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
  • 6.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
    • 6.4.1.North America
      • 6.4.1.1. U.S.
      • 6.4.1.2. Canada
      • 6.4.1.3. Rest of North America

7. UK and European Union Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
  • 7.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
  • 7.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.4.1.UK and European Union
      • 7.4.1.1. UK
      • 7.4.1.2. Germany
      • 7.4.1.3. Spain
      • 7.4.1.4. Italy
      • 7.4.1.5. France
      • 7.4.1.6. Rest of Europe

8. Asia Pacific Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
  • 8.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
  • 8.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.4.1.Asia Pacific
      • 8.4.1.1. China
      • 8.4.1.2. Japan
      • 8.4.1.3. India
      • 8.4.1.4. Australia
      • 8.4.1.5. South Korea
      • 8.4.1.6. Rest of Asia Pacific

9. Latin America Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
  • 9.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
  • 9.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.4.1.Latin America
      • 9.4.1.1. Brazil
      • 9.4.1.2. Mexico
      • 9.4.1.3. Rest of Latin America

10. Middle East and Africa Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
  • 10.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
  • 10.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
    • 10.4.1.Middle East and Africa
      • 10.4.1.1. GCC
      • 10.4.1.2. Africa
      • 10.4.1.3. Rest of Middle East and Africa

11. Company Profile

  • 11.1. GlaxoSmithKline Plc
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Bellicum Pharmaceuticals
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Novartis AG
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Acceleron Pharma
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Johnson & Johnson
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Merck & Co Inc.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Alnylam Pharmaceuticals Inc.
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Calimmune Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Editas Medicine Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Gilead Sciences Inc.
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives